Sieger Healthcare Acquisition Corp
MANAGEMENT & BOARD
Executive Officers
Xuan Sun, 46
Chief Executive Officer and Chairman
Mr. Sun has 20 years of experience in healthcare-focused investments, investment banking and scientific research. Mr. Sun is currently an independent director of Bombax Healthcare Acquisition Corporation, a blank check company. Mr. Sun served as Executive Director and Vice Chairman of Shenzhen Hepalink Pharmaceutical Group Co. Ltd., (“Hepalink”), a leading Hong Kong- and Shenzhen-listed global pharmaceutical company. During his tenure at Hepalink, Mr. Sun was responsible for investments, new product development, capital market strategies, and investor relations. Notably, Mr. Sun led and managed Hepalink’s investments in Kymab Ltd., a U.K.-based clinical-stage biopharmaceutical company focused on immunology, immuno-oncology, hematology and infectious disease acquired by Sanofi in 2021 for approximately $1.5 billion (approximately $1.1 billion in upfront payments and up to $350 million in milestone payments). Mr. Sun also served as the Executive Chairman of Cytovance, Hepalink’s U.S.-based contract development and manufacturing organization (CDMO) platform, where the backlog of the CDMO business achieved a 98% year-on-year growth and reached approximately $100 million at the end of 2020. Prior to Hepalink, Mr. Sun served as a Managing Director and Co-Head of Global Healthcare Investment of Yunfeng Capital Co., Ltd., a multi-billion dollar private equity fund co-founded by Alibaba Group Founder Jack Ma. Prior to Yunfeng, Mr. Sun was an investment banker at UBS AG in New York and Hong Kong, ultimately serving as a Managing Director and Head of Asia Healthcare Group. At UBS, Mr. Sun led over 50 healthcare mergers and acquisitions, and equity and debt financing transactions, a majority of which involved listed securities traded on the major stock exchanges globally. Prior to UBS AG, Mr. Sun was a Healthcare Equity Research Analyst at Morgan Stanley & Co. in New York. Prior to Morgan Stanley & Co., Mr. Sun was a Research Scientist at Bristol-Myers Squibb. Mr. Sun graduated from Vanderbilt University with a Bachelor of Science degree in chemistry, obtained a masters in pharmacology from Columbia University, and graduated with distinction from New York University Stern School of Business with a Master of Business Administration degree.
Yiu-Ting Tsoi, 49
Chief Financial Officer, President and Director
Mr. Tsoi has over 20 years of experience in corporate finance and investment banking. Mr. Tsoi is currently the Co-Chief Executive Officer of Infinity-HB Investment Management, the general partner of a Technology, Media and Telecommunications venture capital fund affiliated with the Infinity Group, a global investment group which has 19 offices worldwide. Mr. Tsoi was also a Managing Director of Paradigm Advisors, a boutique investment bank from 2019 to 2021. Prior to Paradigm Advisors, Mr. Tsoi served as the Chief Financial Officer of China South City Holdings, a publically-traded and leading developer and operator of large-scale integrated logistics, from 2016 to 2018. Prior to China South City Holdings, Mr. Tsoi worked at JP Morgan from 2010 to 2016 ultimately as the Head of Hong Kong Corporate Finance from 2014 to 2016. During Mr. Tsoi’s tenure with JP Morgan, he sourced and executed various transactions across Asia, including mergers and acquisitions, initial public offerings, equity offerings and debt offerings. Prior to JP Morgan, Mr. Tsoi held different investment banking roles with the Royal Bank of Scotland, ABN AMRO, Cazenove Asia, and BNP Paribas. Mr. Tsoi holds a Bachelor in Business Administration degree from the Chinese University of Hong Kong, a Master’s degree in real estate from the University of Cambridge, and a Master of Business Administration from the London Business School. Mr. Tsoi is also a Chartered Certified Accountant (FCCA).
Joel Chang, 53
Senior Advisor
Mr. Chang has extensive experience in private equity, capital markets transactions and mergers and acquisitions. Mr. Chang currently serves as an Independent Non-Executive Director of OCI International Holdings Limited (0329.HK), a publicly listed investment and investment management firm focused on exploring opportunities in relation to China markets. Mr. Chang also partnered with CMBC International in 2015 and established a private equity fund with a focus on healthcare and other industries. Prior to Intellectus Capital, Mr. Chang co-founded AID Partners, an investment vehicle that launched two private equity funds, one of which was financed and supported by CV Starr under Mr. Maurice Greenberg, and AID Genomics, an international group of medical technology companies specialized in the diagnosis and therapy of cancer and infectious diseases. Prior to AID Partners, Mr. Chang served as the Chief Investment Officer of Investec Asia, the direct investment arm of Investec Bank, where he completed various direct investment transactions. Before joining Investec Bank, Mr. Chang was an investment banker at BNP Paribas Peregrine. Mr. Chang has also previously served as a key executive and/or director at Mason Group Holdings Limited (0273.HK), spearheading its healthcare investment initiatives, Kingsoft Corporation Ltd. (3888.HK) and Orange Sky Golden Harvest (1132.HK). Mr. Chang holds a Bachelor in Economics degree from Monash University. Mr. Chang is also a CPA member of CPA Australia (CPAA) and Hong Kong Institute of Certified Public Accountants (HKICPA).
Board of Directors
Eden Wong, 51
Independent Director Nominee
Mr. Wong has more than 25 years of experience in the investment banking and asset management industries. Mr. Wong is the Founder, Chairman and CEO of Viipark Financial Holdings Co., Ltd., a boutique investment bank for institutions, corporations, family offices and high net worth individual investors across Asia. Mr. Wong is also an independent director of AID Genomics Group Limited, a medical technology company specialized in the diagnosis and therapy of cancer and infectious diseases. Prior to founding Viipark, Mr. Wong founded and served as the Managing Director to East Park Investment Management Co. Ltd., a Hong Kong based independent alternative asset management company, which previously managed three different hedge funds in 2010. Prior to establishing East Park, Mr. Wong was an Executive Director at Goldman Sachs (Asia) L.L.C. in Hong Kong from 2006 to 2010 where he worked in the Fixed Income, Currencies and Commodities Division and Investment Management Division, respectively. Prior to Goldman Sachs (Asia) L.L.C. from 1998 to 2006, Mr. Wong worked at Credit Suisse First Boston, ING Barings, Barclays Capital and The HSBC Group from 1998 to 2006. Mr. Wong holds a Master of Business Administration degree (with honors) from the University of Chicago Booth School of Business, a Bachelor of Commerce from the University of Melbourne and a Bachelor of Law (with honors) from the University of London.
Allan Bradley, 61
Independent Director Nominee
Dr. Bradley has more than 25 years of experience in the life sciences and biotechnology industries as a world-renowned researcher and serial entrepreneur. Dr. Bradley founded multiple companies, including Kymab Ltd., acquired by Sanofi for up to approximately $1.5 billion (approximately $1.1 billion in upfront payments and up to $350 million in milestone payments), Lexicon Pharmaceuticals Inc., (NASDAQ: LXRX), Spectral Genomics Inc., acquired by PerkinElmer in 2006, and PetMedix Ltd. since 2018, a company that develops therapeutic antibodies for animals. He is Chief Scientific Officer of Kymab and PetMedix. Dr. Bradley is Emeritus Director of the Wellcome Trust Sanger Institute where he served as the Executive Director from 2000 to 2010. He is a Fellow to the Royal Society and the Academy of Medical Sciences. Dr. Bradley was appointed as an Investigator at Howard Hughes Medical Institute from 1993 to 2000 and was a professor of Baylor College of Medicine, Houston, Texas from 1987 to 2000. Dr. Bradley holds a Bachelor of Arts, Master of Arts, and PhD from the University of Cambridge.
Feng Luo, 57
Independent Director Nominee
Dr. Luo has more than 20 years of experience in the pharmaceutical industry. Dr. Luo has led and supported multiple U.S. New Drug Application (“NDA”) programs for novel oncology drugs, including the EGFR inhibitor, Abivertinib, the FGFR inhibitor, Erdafitinib, and the BCR-ABL inhibitor, Dasatinib. Dr. Luo also has extensive experience in oncology R&D, translational research and clinical pharmacology, having participated in clinical development of numerous small molecule and antibody programs, against both validated and novel targets. In addition, Dr. Luo has extensive experience in licensing and business development, having participated in the evaluation of multiple external collaborations, partnerships, in-licensing transactions, and acquisitions. Dr. Luo currently serves as Chief Development Officer, Head of Clinical and Preclinical Development at Overland Pharmaceuticals Inc., a premier biopharmaceutical company, where he is primarily responsible for the overall development strategy of Overland Pharmaceuticals’s portfolio of differentiated therapeutics. Prior to Overland Pharmaceuticals, Dr. Luo served as Senior Vice President, Chief Development Officer at Ionova, a clinical stage biotech company, where his primary responsibility is to oversee the clinical development organization and lead global clinical development programs and portfolio strategy. Dr. Luo was also Senior Vice President and Chief Clinical Development Officer at Adagene Inc. (NASDAQ: ADAG) (2019?–?2020) and Vice President and Head of Global Clinical Development at ACEA Therapeutics Inc. (2017?–?2019). Prior to ACEA Therapeutics, Dr. Luo served in various senior roles in large pharmaceutical organizations, including the Asia Pacific Clinical Program Lead at Johnson & Johnson (2009?–?2017), Senior Director at Daichi-Sankyo (2007?–?2009), and Senior Research Investigator at Bristol Myers Squibb (2000?–?2007). Dr. Luo completed his post-doctorate fellowship training at the Cancer Institute of New Jersey, received his PhD at University of North Carolina at Chapel Hill, received his Master of Science degree in biochemistry from Bowling Green State University, and received his Bachelor of Science degree in chemistry from Peking University.